192 related articles for article (PubMed ID: 31866437)
1. Severe asthma in the US population and eligibility for mAb therapy.
Akenroye A; McCormack M; Keet C
J Allergy Clin Immunol; 2020 Apr; 145(4):1295-1297.e6. PubMed ID: 31866437
[No Abstract] [Full Text] [Related]
2. The challenge of choosing the correct biologic for the correct asthma patient.
Sriaroon P; Casale TB
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):385-386. PubMed ID: 30290891
[No Abstract] [Full Text] [Related]
3. Biologics in the treatment of severe asthma.
Quirce S; Phillips-Angles E; DomÃnguez-Ortega J; Barranco P
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():45-49. PubMed ID: 29108767
[TBL] [Abstract][Full Text] [Related]
4. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.
Walsh GM
Expert Rev Clin Immunol; 2017 Feb; 13(2):143-149. PubMed ID: 27459348
[TBL] [Abstract][Full Text] [Related]
5. Combination biologic therapy for severe persistent asthma.
Ortega G; Tongchinsub P; Carr T
Ann Allergy Asthma Immunol; 2019 Sep; 123(3):309-311. PubMed ID: 31251970
[No Abstract] [Full Text] [Related]
6. Severe asthma: When to resort to biological agents.
Tenero L; Rossignoli S; Piacentini G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
[TBL] [Abstract][Full Text] [Related]
7. Eosinophilic and Noneosinophilic Asthma.
Carr TF; Zeki AA; Kraft M
Am J Respir Crit Care Med; 2018 Jan; 197(1):22-37. PubMed ID: 28910134
[No Abstract] [Full Text] [Related]
8. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
9. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
10. Asthma versus chronic obstructive pulmonary disease, the Dutch versus British hypothesis, and role of interleukin-5.
Chambliss JM; Sur S; Tripple JW
Curr Opin Allergy Clin Immunol; 2018 Feb; 18(1):26-31. PubMed ID: 29257776
[TBL] [Abstract][Full Text] [Related]
11. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
12. Selecting the right biologic for your patients with severe asthma.
Manka LA; Wechsler ME
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):406-413. PubMed ID: 30056149
[TBL] [Abstract][Full Text] [Related]
13. Association of antieosinophil therapy with decreased body mass index in patients with severe asthma: A preliminary retrospective analysis.
Kuruvilla M; Patrawala M; Levy JM; Shih J; Lee FE
Ann Allergy Asthma Immunol; 2019 Jun; 122(6):649-650. PubMed ID: 30953786
[No Abstract] [Full Text] [Related]
14. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; MartÃnez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
15. How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?
Upham JW; Jurak LM
Clin Exp Allergy; 2020 Sep; 50(9):994-1006. PubMed ID: 32569412
[TBL] [Abstract][Full Text] [Related]
16. Atopic dermatitis is an important comorbidity in severe asthma.
Lee JK; Han D
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):661-662. PubMed ID: 29496463
[No Abstract] [Full Text] [Related]
17. What is the current role of biologics in the management of patients with severe refractory asthma?
Draikiwicz S; Oppenheimer J
Ann Allergy Asthma Immunol; 2016 May; 116(5):383-7. PubMed ID: 27153737
[No Abstract] [Full Text] [Related]
18. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma.
Moore WC; Panettieri RA; Trevor J; Ledford DK; Lugogo N; Soong W; Chipps BE; Carr W; Belton L; Gandhi H; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2020 Sep; 125(3):294-303.e1. PubMed ID: 32304877
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
20. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
Wu AY; Sur S; Grant JA; Tripple JW
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
